text:
Article Date: 3/1/2014
Study: Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration
Sponsor: Bioheart, Inc.
Purpose: To evaluate the treatment of dry AMD with adipose stem cell implantation
Design: Interventional, Single Group, Open Label, Treatment
Number of Patients: 100
Inclusion Criteria: Dry AMD; VA in the study <20/200
Exclusion Criteria: Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study; inability to undergo syringe liposuction procedure or have any medical problems that contraindicate the procedure; life expectancy < 6 months due to concomitant illnesses; vitrectomized eyes; exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study
Information: email@example.com
Study: NEAMD: Non-exudative Age-related Macular Degeneration
Sponsor: Oregon Health and Science University
Purpose: To use OCT technology to compare how the retinal anatomy and blood flow differ within three severity groupings of non-exudative age-related macular degeneration
Design: Observational, Case Control, Prospective
Number of Patients: 20
Inclusion Criteria: Presence of mild, moderate or severe NEAMD; media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs; vision better than 20/200
Exclusion Criteria: Inability to maintain stable fixation for OCT imaging. A condition that, in the opinion of the investigator, would preclude participation in the study (eg, unstable medical status including blood pressure, cardiovascular disease, and glycemic control); a concurrent ocular pathology that may contribute to vision loss (eg, CNV, glaucoma, visually significant cataract, optic neuropathy, diabetic retinopathy, history of retinal surgery) or interfere with acquisition of high-quality images; blood pressure > 180/110
Information: (503) 494-3000
Study: I-TEAM: Intervention Trial in Early Age-related Macular Degeneration
Sponsor: Newtricious R&D BV
Purpose: To assess whether there is a change in visual function and status of the retina after a year of intervention in subjects with early signs of age-related macular degeneration
Design: Randomized, Efficacy, Parallel Assignment, Double-blind, Treatment
Number of Patients: 120
Inclusion Criteria: Many small drusen, or a few intermediate-sized (63-124 micrometers in diameter) drusen, or macular pigmentary changes
Exclusion Criteria: Ocular media opacity (severe cataract); history of active small bowel disease or resection; atrophic gastritis; hyperlipidemia (LDL >120 mg/dL or triglycerides >400 mg/dL)
Information: email@example.com
Study: Study on Visual Function Impairments in Dry Age-related Macular Degeneration
Sponsor: Duke University
Purpose: To submit enrollees to the visual function testing
Design: Observational, Prospective
Number of Patients: 190
Inclusion Criteria: Has been diagnosed with dry age-related macular degeneration stages 1-3
Exclusion Criteria: Presence of retinal pathology such as central geographic atrophy, hemorrhage or retinal fluid, and other macular pathology other than AMD
Information: (919) 684-9010
Study: SEATTLE: Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride (SEATTLE)
Sponsor: Acucela, Inc.
Purpose: To determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration
Design: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blind, Treatment
Number of Patients: 440
Inclusion Criteria: Clinical diagnosis of GA associated with AMD
Exclusion Criteria: Active CNV or presence of an active ocular disease; known serious allergy to the fluorescein sodium for injection in angiography; pre-specified laboratory abnormalities at screening; treatment with any investigational study drug within 30 days of screening or device (within 60 days of screening)
Information: email@example.com
Study: A Safety Study of CNTO 2476 in Patients With AMD
Sponsor: Janssen Research & Development
Purpose: To evaluate the safety and tolerability of CNTO 2476 administered subretinally
Design: Randomized, Safety/Efficacy, Single Group Assignment, Open Label, Treatment
Number of Patients: 56
Inclusion Criteria: Bilateral GA of the macula caused by AMD
Exclusion Criteria: Exudative AMD; evidence of other significant ophthalmologic disease; ocular hypertension; previous cell therapy other than blood components
Information: email@example.com
Study: Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With GA Secondary to AMD
Sponsor: GlaxoSmithKline
Purpose: To determine the safety and efficacy of GSK933776 in the treatment of GA secondary to AMD
Design: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blind
Number of Patients: 162
Inclusion Criteria: Evidence of AMD confirmed by the presence of at least 1 drusen ≥125 microns; well-demarcated GA due to AMD
Exclusion Criteria: Additional eye disease that could compromise assessment of BCVA or imaging of the posterior pole; history of CNV; previous treatment for AMD, with the exception of dietary supplements
Information: email@example.com
Study: Safety and Tolerability of Subretinal Transplantation of hESC-derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry AMD
Sponsor: Advanced Cell Technology
Purpose: To evaluate the effect of subretinal injection of human embryonic stem cell-derived RPE cells in patients with dry AMD and to perform exploratory evaluation of potential efficacy endpoints to be used in future studies of RPE cellular therapy
Design: Interventional, Safety, Single Group Assignment, Open Label
Number of Patients: 12
Inclusion Criteria: Advanced dry AMD with evidence of one or more areas of > 250 microns of GA involving the central fovea
Exclusion Criteria: Presence of active or inactive CNV; presence or history of other retinal vascular or degenerative disease other than AMD; history of optic neuropathy
Information: email@example.com
Study: Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration
Sponsor: Alcon Research
Purpose: To evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration
Design: Interventional, Nonrandomized, Parallel Assignment, Open Label, Basic Science
Number of Patients: 24
Inclusion Criteria: Diagnosis of age-related macular degeneration in study eye, as specified in protocol; poor visual acuity in study eye, as specified in protocol; willing to receive meningitis and pneumonia vaccinations at least 2 weeks prior to study treatment
Exclusion Criteria: Treatments to the study eye within 28 days prior to study treatment, as specified in protocol; any disease or medication expected to cause systemic or ocular immunosuppression
Information: firstname.lastname@example.com
Study: Liberty: Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration
Sponsor: Retinal Consultants of Arizona/Genentech
Purpose: To reduce the burden of in office visits and injections
Design: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Open Label, Treatment
Number of Patients: 60
Inclusion Criteria: Choroidal neovascular membrane (CNV) secondary to AMD, as confirmed by the patient's medical history and a documented diagnosis of CNV; the study eye must have received at least 3 anti-Vascular endothelial growth factor (VEGF) treatments prior to the screening visit, with at least 2 anti-VEGF treatments over the preceding 3 months; best-corrected visual acuity (BCVA) of 20/32 to 20/200 Snellen equivalent in the study eye; acute or chronic ocular or periocular infection in the study eye, uveitis or ocular inflammation in the study eye; received PDT in the study eye within 60 days, or laser photocoagulation within 14 days prior to screening
Exclusion Criteria: Choroidal neovascularization in the study eye due to any reason other than age-related macular degeneration; active uncontrolled glaucoma; had any intraocular surgeries in the study eye within 3 months of enrollment or are known or likely candidates for intraocular surgery (including cataract surgery) in the study eye within 1 year of enrollment
Information: firstname.lastname@example.com
Study: A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration
Sponsor: Santen Inc.
Purpose: To assess the safety, tolerability, bioactivity and pharmacokinetics of three concentrations of DE-120 after a single intravitreal injection in subjects with late stage exudative age-related macular degeneration
Design: Interventional, Nonrandomized, Safety/Efficacy, Single Group, Open Label, Treatment
Number of Patients: 9
Inclusion Criteria: Diagnosis of chronic subretinal or intraretinal fluid secondary to exudative age-related macular degeneration in the study eye; at least one lesion in the study eye that meets minimal pathology criteria; visual acuity of ≤ 55 ETDRS letter (20/80 Snellen equivalent) or worse in the study eye, excluding No Light Perception; reasonably clear media and some fixation in the study eye
Exclusion Criteria: Visual acuity of No Light Perception; aphakic or has an anterior chamber intraocular lens in the study eye; use or anticipated use of any intravitreal, periocular or photodynamic therapy in the study eye for the treatment of AMD within a specified time frame prior to Visit 1; uncontrolled glaucoma, chronic hypotony or vitrectomy in the study eye
Information: (415) 268-9059
Study: Phase 1 Study of Topical Ocular PAN-90806 for Neovascular Age-related Macular Degeneration
Sponsor: PanOptica, Inc.
Purpose: To assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration
Design: Interventional, Randomized, Safety, Parallel Assignment, Open Label, Treatment
Number of Patients: 30
Inclusion Criteria: Diagnosis in the study eye of active, pathologic, newly diagnosed and previously untreated, subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD
Exclusion Criteria: History of or current clinical evidence in the study eye of: aphakia, diabetic macular edema, any ocular inflammation or infections, pathological myopia, retinal detachment, advanced glaucoma, and significant media opacity, including cataract
Information: firstname.lastname@example.com
Study: Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
Sponsor: Regeneron
Purpose: To investigate the safety of intravitreal (IVT) REGN2176-3 in patients with neovascular wet age-related macular degeneration
Design: Interventional, Safety, Single Group, Open Label, Treatment
Inclusion Criteria: Active subfoveal choroidal neovascularization (CNV) secondary to wet AMD
Exclusion Criteria: Any prior treatment with an inhibitor of PDGF (platelet-derived growth factor) or PDGFR (platelet-derived growth factor receptor); active neovascular AMD in the fellow eye requiring treatment; scar, fibrosis, or atrophy in the study eye involving the center of the fovea; presence of retinal pigment epithelial tears or rips involving the macula in the study eye; prior vitrectomy in the study eye
Information: email@example.com
Study: ESBA1008 Microvolume Study
Sponsor: Alcon
Purpose: To demonstrate a treatment effect of ESBA1008 applied as microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration
Design: Interventional, Randomized, Efficacy, Parallel Assignment, Single-blind, Treatment
Number of Patients: 26
Inclusion Criteria: Age-related macular degeneration in the study eye; visual acuity within protocol-specified range
Exclusion Criteria: Any treatment for exudative age-related macular degeneration (AMD) other than vitamin supplements; any current or history of macular or retinal disease; any concurrent intraocular condition such as cataract or diabetic retinopathy that, in the opinion of the Investigator, could either require medical or surgical intervention during the course of the study to prevent or treat visual loss
Study: Pilot Study of X-82 in Patients With Wet AMD
Sponsor: Xcovery Vision, LLC/Tyrogenex
Purpose: To evaluate the safety and preliminary biologic activity/efficacy of X-82 in patients with wet Age-related Macular Degeneration
Design: Interventional, Safety/Efficacy, Single Group Assignment, Open Label, Treatment
Inclusion Criteria: Active choroidal neovascularization (CNV) associated with AMD, as evidenced on fluorescein angiography (FA) and OCT; no previous treatment with anti-VEGF therapy or prior anti-VEGF therapy with evidence of response to treatment and the need for additional treatment; Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA 20/32 to 20/320 in the study eye(s); adequate bone marrow function
Exclusion Criteria: Previous treatment with photodynamic therapy (PDT) within 4 months of screening in the study eye; CNV due to causes other than AMD; geographic atrophy involving the foveal center in the study eye; any retinal vascular disease or retinal degeneration other than AMD in the study eye
Information: firstname.lastname@example.com
Study: RESCUE: Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept
Sponsor: Northern California Retina Vitreous Associates/Genentech
Purpose: To determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept
Design: Interventional, Nonrandomized, Efficacy, Parallel Assignment, Open Label, Treatment
Number of Patients: 8
Inclusion Criteria: Best-corrected ETDRS VA between 20/25 to 20/320; total area of subretinal hemorrhage and/or fibrosis comprising less than 50% of lesion
Exclusion Criteria: History of prior vitrectomy surgery; previous treatment with photodynamic therapy, radiation, or any other intravitreal drug delivery, such as dexamethasone or triamcinolone
Study: Prospective Randomized Trial of Proton Beam Combined With Anti-VEGF Therapy for Exudative AMD
Sponsor: University of California, Davis
Purpose: To test the hypothesis that proton beam irradiation combined with intravitreal anti-VEGF therapy is safe and potentially more effective than intravitreal anti-VEGF therapy alone in eyes with exudative AMD
Design: Randomized, Placebo Control, Safety/Efficacy, Parallel Assignment, Double-blind, Treatment
Number of Patients: 45
Inclusion Criteria: VA 20/40 to 20/400; lesion size <12 DA; submacular hemorrhage <75% of total lesion and not involving foveal center; submacular fibrosis <25% of total lesion
Exclusion Criteria: Previous treatment with photodynamic therapy or thermal laser; anti-VEGF therapy within 6 weeks; intravitreal or sub-Tenon's Kenalog within 6 months
Information: (916) 734-6074
Study: GEM: Phase I Dose Escalation Safety Study of RetinoStat in Advanced AMD
Sponsor: Oxford BioMedica
Purpose: To examine the safety of an experimental gene transfer agent, RetinoStat, designed to treat neovascular AMD
Design: Interventional, Safety, Single-group Assignment, Open Label, Treatment
Number of Patients: 18
Inclusion Criteria: Clinical diagnosis of AMD with active CNV that shows evidence of leakage; BCVA less than or equal to 20/200
Exclusion Criteria: Significant ocular abnormalities that prevent retinal assessment; treatment with steroids within three months of screening; treatment with anti-VEGF therapy within one month of screening
Information: email@example.com
Study: NVAMD: Neovascular Age-related Macular Degeneration
Purpose: To assess the utility of OCT angiography in the evaluation of NVAMD
Number of Patients: 15
Inclusion Criteria: Presence of neovascular AMD confirmed by fluorescein dye leakage on angiogram or presence of at least one of the following on OCT: subretinal fluid, intraretinal fluid, or sub-retinal pigment epithelial fluid; treatment naïve group consists of individuals who have not received any treatment for neovascular AMD in the study eye; votive treatment group consists of individuals who have received treatment with an anti-VEGF agent (Avastin, Lucentis, Macugen, or Eylea) 6 weeks prior enrollment visit
Exclusion Criteria: Inability to maintain stable fixation for OCT imaging; significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant; a condition that, in the opinion of the investigator, would preclude participation in the study (eg, unstable medical status including blood pressure, cardiovascular disease, and glycemic control); blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible; prior macular laser treatment; Subretinal hemorrhage or fibrosis >50% of choroidal neovascular lesion; visual acuity 20/200 or worse; an ocular condition is present such that, in the opinion of the investigator, may alter the retinal anatomy (eg, epiretinal membrane); an ocular condition is present (other than neovascular AMD) that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (eg, vein occlusion, uveitis or other ocular inflammatory disease, etc.)
Study: Effects of Sildenafil on Choroidal Thickness in AMD
Purpose: To compare choroidal thickness changes after a single-dose sildenafil treatment in AMD patients compared with age-matched controls
Design: Interventional, Nonrandomized, Efficacy, Single Group, Open Label
Number of Patients: 80
Inclusion Criteria: Has been diagnosed with AMD
Exclusion Criteria: History of previous photodynamic therapy (PDT), intravitreal corticosteroid injection, macular focal laser photocoagulation, panretinal photocoagulation, ocular ionizing irradiation, transpupillary thermotherapy, or any vitreoretinal surgeries
Information: (919) 797-9111
Study: ATLAS: Repeated Eye Injections of Aflibercept for Treatment of Wet AMD
Sponsor: Brian Burke, MPH/Regeneron
Purpose: To evaluate the visual outcome and number of injections required during an OCT- guided treat and extend regimen with intravitreal aflibercept for treatment of subfoveal neovascular AMD
Design: Interventional, Nonrandomized, Parallel Assignment, Open Label, Treatment
Number of Patients: 40
Inclusion Criteria: Only one eye for each patient demonstrating a pre-treatment acuity of 20/25 - 20/320 is eligible; patients cannot have concurrent progressive retinal disease
Exclusion Criteria: Prior treatment for NVAMD in the study eye; prior experimental treatment of NVAMD; prior treatment with systemic anti-VEGF agents; prior treatment with verteporfin
Information: firstname.lastname@example.com
Study: Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
Sponsor: Arshad Khanani/Genentech
Purpose: To compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept
Design: International, Nonrandomized, Parallel Assignment, Single-blind, Treatment
Inclusion Criteria: New onset Neovascular Age-Related Macular Degeneration; previously treated Neovascular Age-Related Macular Degeneration with Lucentis or Eylea intravitreal injections; visual acuity of 20/400 or better; no history of Post injection pain or inflammation with prior treatments
Exclusion Criteria: History of Endophthalmitis in either eye; uncontrolled or symptomatic Dry Eye Syndrome; history of Anterior or Posterior Uveitis; history of Post injection pain or inflammation with prior treatments; recent thromboembolic event(<3 months)
Information: email@example.com
Study: Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) AMD
Sponsor: Ohr Pharmaceuticals, Inc.
Purpose: To evaluate the safety and efficacy of topical squalamine lactate eye drops in treating patients with neovascular AMD
Inclusion Criteria: A diagnosis of CNV secondary to AMD with total lesion area ≤ 12 disc areas with CNV affecting at least 50% of the total lesion area confirmed by FA
Exclusion Criteria: Neovascularization secondary to any condition other than AMD in the study eye; blood occupying greater than 50% of the AMD lesion
Information: email@example.com
Study: Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging (PVOCT)
Sponsor: University of California, San Francisco
Purpose: To determine whether phase variance optical coherence tomography (PVOCT), a software-based OCT image processing technology, can be used to generate angiographic images of the retinochoroidal vasculature that are comparable to those produced by fluorescein angiography
Design: Observational, Cohort, Prospective
Number of Patients: 78
Exclusion Criteria: Any patients with ocular media opacities which prevent clear evaluation of the fundus by either FA or OCT
Information: email@example.com
Study: Nexus: Efficacy and Safety Study of iSONEP With and Without Lucentis/Avastin to Treat Age-related Macular Edema
Sponsor: Lpath, Inc./Pfizer
Purpose: To determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis or Avastin in subjects with wet AMD
Number of Patients: 160
Inclusion Criteria: Subjects who have received 3-10 IVT injections of Lucentis or Avastin within 12 months prior to screening; active subfoveal CNV secondary to AMD; presence of residual subretinal or intraretinal fluid on Cirrus or Spectralis SDOCT; SDOCT in the 1 mm central macular subfield on the retinal map analysis of ≥250 μm at screening
Exclusion Criteria: Most recent IVT injection of Lucentis or Avastin <28 days and >65 days prior to screening; previous PDT or Macugen at any time point; focal thermal laser or grid laser within 3 months prior to Day 0; use of IVT, sub-Tenon's or subconjunctival steroids within 3 months prior to Day 0; use of topical ophthalmic corticosteroids 2 weeks prior to Day 0
Information: email@example.com
Study: Safety and Efficacy of Intravitreal LFG316 in Wet Age-related Macular Edema
Sponsor: Novartis
Purpose: To assess the safety and efficacy of LFG316 in patients with AMD
Design: Randomized, Parallel Assignment, Single-blind, Treatment
Number of Patients: 57
Inclusion Criteria: BCVA of 60 letters or less in the study eye; an active CNV membrane attributable to neovascular AMD
Exclusion Criteria: History of recurrent nonresponse to anti-VEGF therapy; retinal disease other than AMD; CNV not due to AMD
Information: (862) 778-8300
Study: Addition of 20 mg/Day Zeaxanthin to Triple Therapy Treatment Options for AMD
Sponsor: The Retina Center of St. Louis County, P.C./ZeaVision, Inc.
Purpose: To evaluate whether 20 mg per day of oral zeaxanthin as a supplement to patients with CNV and exudative AMD undergoing combination therapy with bevacizumab, dexamethasone and PDT laser photocoagulation improves outcomes
Design: Observational, Case Control, Retrospective
Number of Patients: 200
Inclusion Criteria: Subjects must have AMD with a CNV membrane either classic or occult in at least one eye; preoperative BCVA equal to or greater than 19 letters on the ETDRS diabetic retinopathy study chart (20/400 Snellen); media clarity, pupillary dilation and subject cooperation sufficient for accurate OCT and angiographic assessment
Exclusion Criteria: Retinal disease not AMD; any presumed ocular infections, ie, bacterial, viral, parasitic, or fungal in either eye at the baseline visit; contraindication to pupillary dilation in either eye
Uncontrolled systemic disease.
Information: firstname.lastname@example.com
Study: A Study of RO6867461 Administered in Single-Ascending-Dose in Patients With Wet Age-related Macular Degeneration
Sponsor: Hoffman-La Roche
Purpose: To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6867461 in patients with wet age-related macular degeneration
Design: Interventional, Nonrandomized, Safety, Single-group Assignment, Open Label, Treatment
Inclusion Criteria: AMD; BCVA between 20/40 and 20/400; evidence of leakage due to CNV
Exclusion Criteria: CNV in other eye due to cause other than AMD; any intraocular inflammation
Information: email@example.com
Study: Study of Dark Adaptation in Age-related Macular Degeneration
Sponsor: National Eye Institute
Purpose: To evaluate the effectiveness of using a dark adaptation protocol to identify and monitor early to middle dry AMD
Inclusion Criteria: Group 0: No large drusen or advanced AMD; Group 1: At least one large drusen in the study eye and no large drusen or advanced AMD in the fellow eye; Group 2: Bilateral large drusen with or without RPE hypo/hyperpigmentary changes; Group 3: At least one large drusen in the study eye and advanced AMD in the fellow eye
Exclusion Criteria: Advanced AMD
Information: firstname.lastname@example.com
Study: CFH&AMD: Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Sponsor: Department of Veterans Affairs
Purpose: To test the hypothesis that smoking increases AMD by increasing complement activation and that this is positively correlated with known disease variations in the CFH gene
Number of Patients: 300
Exclusion Criteria: Ocular diseases that might simulate AMD or preclude its diagnosis
Information: email@example.com
Study: Proton Radiation Therapy for Macular Degeneration
Sponsor: University of Florida
Purpose: To determine if proton radiation therapy can provide effective and safe treatment for subfoveal neovascularization membrane
Number of Patients: 10
Inclusion Criteria: Patients with subfoveal neovascular membranes identified on fluorescein angiography; visual acuity (best corrected vision) 20/200 or worse in affected eye; patients must have had prior treatment for macular degeneration with Avastin (bevacizumab) or Lucentis (ranibizumab)
Exclusion Criteria: History of diabetes
Information: (877) 686-6009
Study: A Phase 3 Safety and Efficacy Study of Fovista™ (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Sponsor: Ophthotech Corp.
Purpose: To evaluate the safety and efficacy of intravitreal administration of Fovista™ administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration
Number of Patients: 622
Inclusion Criteria: Subfoveal choroidal neovascularization (CNV) due to AMD with some classic component
Exclusion Criteria: Any prior treatment for AMD in the study eye prior to the Day 1 visit, except oral supplements of vitamins and minerals; any prior intravitreal treatment in the study eye prior to the Day 1 visit, regardless of indication (including intravitreal corticosteroids); any intraocular surgery or thermal laser within three months of trial entry; any prior thermal laser in the macular region, regardless of indication; subjects with subfoveal scar or subfoveal atrophy are excluded; diabetes mellitus
Information: email@example.com
Study: A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
Sponsor: Pfizer
Purpose: To provide an alternative mechanism to treat Diabetic Macular Edema
Inclusion Criteria: Patients with diabetes mellitus (Type 1 or Type 2) showing DME; reduced visual acuity resulting from retinal thickening
Exclusion Criteria: Severe impaired renal function; any intraocular condition or previous surgery in either eye that would likely require medical or surgical intervention during the study duration or if allowed to progress untreated for the 16 weeks of study duration, would likely contribute to a reduction in visual acuity
Information: https://trialinfoemail.pfizer.com/pages/landing.aspx
Study: Safety and Efficacy of AKB-9778 as Monotherapy or Adjunctive to Ranibizumab Compared to Ranibizumab Monotherapy in Subjects With Diabetic Macular Edema
Sponsor: Aerpio Therapeutics
Purpose: To evaluate the safety and efficacy of AKB-9778 administered as daily subcutaneous injections with and without monthly intravitreal injections of ranibizumab for 3 months in patients with diabetic macular edema
Inclusion Criteria: Diagnosis of diabetes mellitus (type 1 or type 2); decrease in vision in the study eye determined to be primarily the result of DME; definite retinal thickening due to diffuse DME involving the central macula in the study eye; central subfield thickness of at least 325 µm by SD-OCT with presence of intraretinal fluid in the study eye
Exclusion Criteria: Hemoglobin A1C (HbA1C) ≥ 12.0% at screening; history of non-infectious uveitis; decrease in visual acuity due to causes other than DME in the study eye
Information: firstname.lastname@example.com
Study: Nepafenac Once Daily for Macular Edema
Purpose: To demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery
Number of Patients: 590
Inclusion Criteria: Planned cataract extraction by phacoemulsification with implantation of a posterior chamber intraocular lens; history of Type 1 or 2 diabetes and non-proliferative diabetic retinopathy (NPDR) (mild, moderate, or severe) in the study eye; BCVA of 73 letters or worse in the study eye with expectation of improvement after surgery
Exclusion Criteria: Pre-existing macular edema in the study eye; history in the study eye of retinal detachment, wet age-related macular degeneration, or prior procedures; planned cataract surgery in the fellow eye prior to the Day 90 postoperative study visit or through study exit
Study: Dextromethorphan for Diabetic Macular Edema
Purpose: To see if dextromethorphan can help treat diabetic macular edema
Design: Interventional, Safety/Efficacy, Single Group, Open Label, Treatment
Inclusion Criteria: BCVA ETDRS score of 34 letters or better (ie, 20/200 or better) Definite retinal thickening due to diabetic macular edema based on clinical examination that is not refractory to further therapy
Exclusion Criteria: An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (eg, foveal atrophy, pigmentary changes, dense subfoveal hard exudates, non-retinal condition); an ocular condition is present
Information: firstname.lastname@example.com
Study: ROTATE: Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab
Sponsor: Southeast Retina Center, Georgia/Genentech
Purpose: To determine the safety and efficacy of intravitreally administered 0.3mg ranibizumab in subjects with persistent Diabetic Macular Edema (DME) after recent and frequent bevacizumab (at least 2 bevacizumab intravitreal injections within 2 months prior to enrollment and at least 6 bevacizumab injections within 9 months of enrollment)
Inclusion Criteria: Central-involved DME in study eye (OCT CSF >=275 µm on Heidelberg Spectralis spectral domain OCT with evidence of intraretinal or subretinal fluid or cysts); definite retinal thickening due to diabetic macular edema involving the center of the macula
Exclusion Criteria: Known allergy to ranibizumab; acute cardiovascular event requiring hospitalization within the past 3 months; systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomization or anticipated use during the study; macular edema is considered to be due to a cause other than DME
Information: email@example.com
Study: OPERA: Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl
Sponsor: Cleveland Clinic/Allergan
Purpose: To examine the use of the dexamethasone implant (Ozurdex) in patients with diabetic macular edema associated with an epiretinal or preretinal membrane requiring surgical intervention
Design: Interventional, Single Group Assignment, Open Label, Treatment
Inclusion Criteria: Patients who are undergoing pars plana vitrectomy for: epiretinal membrane/vitreomacular traction or diabetic macular edema; patients with macular edema as measured by OCT (at least 250 µm central subfoveal thickness)
Exclusion Criteria: History of active inflammatory eye disease (uveitis) (within 3 months); history of ocular malignancy and/or ocular/orbital irradiation; history of recent retinal vein occlusion (within 6 months)
Information: email@example.com
Study: Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery
Sponsor: Lahey Clinic
Purpose: To assess the safety and efficacy of Ozurdex after vitrectomy
Design: Randomized, Safety/Efficacy, Single-group Assignment, Double-blind, Treatment
Inclusion Criteria: Patients with DME secondary to diabetes mellitus involving the center of the macula OCT thickness is > 300 µm with intraretinal cystic edema; BCVA between 20/40 to 20/400; patient had vitrectomy surgery
Exclusion Criteria: Patient unlikely to benefit from intravitreal Ozurdex due to macular ischemia, atrophy, or other condition; patient with history of steroid response with IOP >35 mm Hg or requirement to be on > 2 glaucoma medications following previous steroid injection
Information: email@example.com
Study: CDDR: Computer Detection of Diabetic Retinopathy Compared to Clinical Examination
Sponsor: IDx LLC
Purpose: To determine whether computer detection of the severity of diabetic retinopathy including the presence of clinically significant macular edema is not inferior to the detection using a dilated eye examination by a Board-certified ophthalmologist
Design: Observational, Case-only, Prospective
Number of Patients: 600
Inclusion Criteria: No history of any other retinal vascular disease, glaucoma, or other disease that may affect the appearance of the retina or optic disc (refractive error and ocular surface disease are allowed); other than cataract surgery
Exclusion Criteria: A history of retinal vascular disease other than due to diabetic retinopathy, glaucoma, or other disease that may affect the appearance of the retina or optic disc; previous intraocular surgery other than cataract; previous laser to the retina
Information: (713) 559-5200
Study: Ranibizumab and Bevacizumab for Diabetic Macular Edema
Purpose: To compare the effectiveness of ranibizumab and bevacizumab injections for diabetic macular edema
Design: Interventional, Randomized, Safety/Efficacy, Crossover Assignment, Double-blind, Treatment
Inclusion Criteria: Eye has a BCVA ETDRS score between 20/32 and 20/400; eye has definite retinal thickening or cystic changes due to DME based on clinical exam involving the center of the macula that is not refractory to further therapy as based on the investigator's clinical judgment
Exclusion Criteria: Eye has an ocular condition present such that, visual acuity would not improve from resolution of macular edema (eg, foveal atrophy, pigmentary changes, dense subfoveal hard exudates, non-retinal condition)
Information: email@example.com
Study: Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Sponsor: Retina Macula Institute/Allergan
Purpose: To test the efficacy of a 0.7-mg intravitreal dexamethasone implant on macular leakage and VA for patients with recalcitrant DME
Inclusion Criteria: Presence of NPDR or PDR as confirmed by FA; prior treatment with ≥ 2 intravitreal anti-VEGF injections but no treatment in last 4 weeks; < 0.1 Log OCT decrease in macular edema on high resolution OCT between initial visit and following treatment with ≥2 anti-VEGF injections
Exclusion Criteria: Injection of steroid medication within prior 3 months; evidence of significant GA on fluorescein angiography in the opinion of the treating physician; concurrent ocular disease that would limit visual acuity; prior vitrectomy surgery; use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month prior to day 1; known history of IOP elevation in response to steroid treatment in either eye that resulted in any of the following: a) = 10 mm Hg increase in IOP in response to steroid injection, or b) IOP = 25 mm Hg and required 2 or more anti-glaucoma medications to keep IOP below 21 mm Hg
Information: firstname.lastname@example.com
Study: DAVE: Efficacy and Safety Trial of Intravitreal Injections Combined With PRP for the Treatment of CSME Secondary to Diabetes Mellitus
Sponsor: Genentech/Greater Houston Retina
Purpose: To study the efficacy and safety of ranibizumab injection monotherapy versus a duel therapy of 0.5 mg ranibizumab combined with ultrawide, 200° field angiography guided panretinal photocoagulation in patients with CSME-CI secondary to diabetes mellitus
Design: Interventional, Randomized, Safety/Efficacy, Single Group, Open Label, Treatment
Inclusion Criteria: BCVA of 20/32 to 20/200; high-definition OCT central thickness measurement of ≥ 300 μm; decrease in VA determined to be the result of DME
Exclusion Criteria: Prior ocular treatment; history of vitrectomy surgery in the study eye; any panretinal photocoagulation in the study eye; prior treatment with intraocular or subconjunctival steroids in the study eye; Any concurrent intraocular condition in the study eye (eg, cataract or age related macular degeneration) that, in the opinion of the investigator, could require medical or surgical intervention during the 12-month study period to prevent or treat visual loss that might result from that condition; or if allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of BCVA over the 12-month study period
Information: email@example.com
Study: Protocol V: Treatment for CI-DME in Eyes With Very Good VA Study
Sponsor: Diabetic Retinopathy Clinical Research Network/Genentech
Purpose: To compare the % of eyes that have lost at least 5 letters of visual acuity at 2 years compared with baseline mean visual acuity in eyes with central-involved DME and good VA
Design: Randomized, Interventional, Safety/Efficacy, Parallel Assignment, Single-blind Treatment
Number of Patients: 702
Inclusion Criteria: Best corrected E-ETDRS visual acuity letter score ≥ 79 (approximate Snellen equivalent 20/25 or better) at two consecutive visits within 1 to 28 days; on clinical exam, definite retinal thickening due to DME involving the center of the macula.
Exclusion Criteria: Macular edema is considered to be due to a cause other than DME. a) An eye should not be considered eligible if: (1) the macular edema is considered to be related to ocular surgery such as cataract extraction; or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities (eg, a taut posterior hyaloid or epiretinal membrane) are contributing to the macular edema
Information: email@example.com
Study: A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema
Sponsor: Ampio Pharmaceuticals
Purpose: To evaluate the efficacy of ultra low dose danazol (Optina) for the treatment of diabetic macular edema versus placebo
Number of Patients: 450
Inclusion Criteria: Stable diabetic and metabolic control (no major changes in diabetic or lipid reducing medications for 3 months prior to start of this study as determined by the Investigator)
Exclusion Criteria: Known allergy to any danazol (Cyclomen or Danocrine) or any other non-medicinal component of the danazol test drug (cornstarch, lactose, magnesium stearate, gelatin, and talc); unstable cardiovascular disease or a history of significant heart disease (including unstable angina, acute coronary syndrome, myocardial infarction, or history of coronary revascularization procedure) within 6 months before randomization; an ocular condition is present such that, in the opinion of the Investigator, VA would not improve from resolution of macular edema (eg, foveal atrophy, closure of juxtafoveal capillaries, dense subfoveal hard exudates); history of panretinal scatter photocoagulation (PRP) within 4 months prior to randomization
Information: firstname.lastname@example.com
Study: WAVE: Targeted Laser With Lucentis 0.5mg Versus L Lucentis 0.5mg Monotherapy for Ischemic Central Vein, Hemi Retinal Vein Occlusion and Branch Retinal Vein Occlusion
Sponsor: Charles C Wykoff, PhD, MD/Genentech
Purpose: To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, compared to standard of care
Inclusion Criteria: Subjects with ischemic central retinal vein occlusion with at least 2 consecutive monthly intravitreal injections of anti-VEGF medications with presence of persistent edema in the past 4 months; visual acuity between 20/40 and 20/800, ETDRS visual acuity
Exclusion Criteria: IOP over 30 mm Hg; any previous retinal laser photocoagulation to the study eye; previous intravitreal injection in the study eye of any corticosteroid treatment; inability to assess iris or angle neovascularization (corneal opacity precluding gonioscopy); significant cardiovascular disease or cancer that would prevent follow-up visits or completion of the 12 month study
Information: email@example.com
Study: Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion
Sponsor: Long Island Vitreoretinal Consultants
Purpose: To compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO) after initial treatment with Ozurdex (dexamethasone implant) or Avastin
Inclusion Criteria: ETDRS Visual acuity between 3 and 72 letters and approximate Snellen equivalent of 20/40 to 20/800; OCT Central foveal thickness >250 microns
Exclusion Criteria: History of glaucoma in the study eye with IOP >21 mm Hg on more than one topical medication. Combination drugs are considered more than one medication; history of steroid-related glaucoma (steroid response); previous intraocular injection of steroid medication within 90 days; Avastin (bevacizumab) or Lucentis (ranibizumab) within 60 days; evidence of significant retinal ischemia on fluorescein angiography in the opinion of the treating physician
Information: (732) 797-3984
Study: Minocycline to Treat Branch Retinal Vein Occlusion
Purpose: To test the safety and effectiveness of minocycline as a treatment for branch retinal vein occlusion
Design: Interventional, Randomized, Safety Efficacy, Parallel Assignment, Double-blind, Treatment
Inclusion Criteria: The study eye shows evidence of definite retinal thickening due to a BRVO based on clinical examination involving the center of the macula that is not refractory to further therapy as based on the investigator's clinical judgment; BRVO defined as an eye that had retinal hemorrhage or other biomicroscopic evidence of RVO (eg, telangiectatic capillary bed) and a dilated (or previously dilated) venous system in one or two quadrants or less of the retina drained by the affected vein
Exclusion Criteria: The macular edema is considered to be related to cataract extraction, or clinical examination and/or OCT suggest that vitreoretinal interface disease (eg, a taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular edema, or clinical examination, medical history and/or fluorescein angiography suggest that diabetic retinopathy is the primary cause of the edema; the study eye has a history of a recurrent RVO
Study: ORVO: Ozurdex for Retinal Vein Occlusion Study
Sponsor: Johns Hopkins University/Allergan
Purpose: To measure the pro-permeability factors in the aqueous humor of patients with persistent/recurrent macular edema after an injection of Ozurdex.
Design: Interventional, Nonrandomized, Single Group Assignment, Open Label, Treatment
Inclusion Criteria: Diagnosis of macular edema due to central or branch retinal vein occlusion; intraretinal or subretinal fluid in the macula determined by Spectralis OCT; best corrected visual acuity score in the study eye of 20/30 to 20/400 inclusive (Snellen equivalents using the ETDRS protocol at a distance of 4 meters)
Exclusion Criteria: Scatter laser photo-coagulation or macular photocoagulation within 3 months of study entry in the study eye; intraocular surgery in the study eye within 3 months of study entry; use of intraocular or periocular injection of steroids in the study eye
Information: email@example.com
Study: Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion
Sponsor: Weill Medical College of Cornell University
Purpose: To test thrombolysis with t-PA in several CRVO
Number of Patients: 5
Inclusion Criteria: Severe CRVO diagnosed on presence of relative afferent papillary defect (RAPD) or visual acuity of 20/200 or worse; symptom onset within 2 weeks
Exclusion Criteria: Contra-indication to thrombolysis: active or recent (1 month) internal bleeding, cerebrovascular accident, major organ surgery, major trauma; intracranial neoplasm or vascular malformation, known bleeding diathesis, severe uncontrolled arterial hypertension, pregnancy (women of childbearing age must have a negative serum pregnancy test), or any other condition which in the opinion of the investigators would preclude the use of thrombolytic agents
Information: email@example.com
Study: Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
Sponsor: Brian Burke, MPH
Purpose: To compare dexamethasone implant with rescue intravitreal ranibizumab to monthly intravitreal ranibizumab for the treatment of macular edema secondary to branch or central retinal vein occlusion
Design: Interventional, Randomized, Efficacy, Parallel Assignment, Open Label, Treatment
Inclusion Criteria: Must be diagnosed within two weeks of onset of symptoms; BCVA on initial presentation between 20/40 and 20/320; no contraindications to intravitreal injection of dexamethasone implant or ranibizumab; central foveal thickness greater than 250 µm on SD-OCT
Exclusion Criteria: Patients with age-related macular degeneration; patients with an optic neuropathy; patients with a retinal detachment or history of retinal detachment; patients with a significant epiretinal membrane
Study: RELEASE: Intravitreal Gas for Vitreomacular Adhesion
Sponsor: Northern California Retina Vitreous Associates
Purpose: To determine the effect of an office-based injection of an intravitreal gas bubble as a treatment for symptomatic vitreomacular adhesion
Inclusion Criteria: Patients with symptomatic VMA as defined by clinical and SD-OCT findings: blurred vision, double vision, metamorphopsia, micropsia; Snellen visual acuity: < 20/25 in study eye
Exclusion Criteria: Any macular hole; epiretinal membrane; history of diabetic retinopathy (non-proliferative, proliferative, and/or diabetic macular edema; macular degeneration; retinal vascular occlusion
Information: (650) 988-7480
Retinal Physician, Volume: 12 , Issue: March 2014, page(s): 59-65, 68, 69


text:
Nation braces for government shutdown
At least 800,000 of the nation's 2.1 million federal workers will be required to stay home Tuesday if the government shuts down as a result of Republican grandstanding.
Reckless Republicans push closer to a government shutdown
The chances of avoiding a goverment shutdown in five days are becoming slimmer and slimmer, and the union AFGE is in full mobilization mode against it.
Right wing rebuked in Missouri
Right-wing Republicans in the Missouri legislature and their main financial supporter, libertarian billionaire Rex Sinquefield, suffered a stinging defeat.
Indiana judge finds right-to-work unconstitutional
An Indiana judge ruled the state's "right-to-work" (for less) law is unconstitutional.
Sequester sends San Jose, Calif., rents through roof
Some 17,000 tenants on the Federal Section 8 housing program in Santa Clara County recently received rent hikes of 10 percent or more. The area has very nearly the highest housing cost of any place in the country.

subset: commoncrawl


text:
Sunlight to Spare
In 2009, Dr. Richard Perez, an atmospheric scientist specializing in solar energy at the University of Albany, in New York, compared the world's annual energy consumption with its available fossil, nuclear, and renewable energy resources. The volume of each of the four "finite energy" spheres, above, represents the total recoverable energy reserves in terawatt-years (TWy), while the volume of the remaining "renewable energy" spheres represents yearly potential in terawatt-years. One of Perez's sun facts: The world's available solar energy exceeds its energy consumption by a factor of 1,200.
Graphic by Peter and Maria Hoey
Landscape Image


text:
The Power of Independent Thinking
Anthony Gregory on Marginal Revolution and the Austrians
2011 Summer Seminars for College Students
Recorded: Wednesday, August 3, 2011
This presentation is from our 2011 Challenge of Liberty Summer Seminar for college students, which was held from August 1 to 5, 2011, at Notre Dame de Namur University, Belmont, California.
View videos and more information about the Summer Seminars.
Experts: Anthony GregoryType: Challenge of Liberty SeminarsIssues: Economists
David Theroux on ABC7 on Selling Government Land to Reduce California Deficit
Recorded: Tuesday, September 9, 2008
David Theroux proposes that California sell government land to reduce the states budget crisis in an ABC 7 MoneyScope report.
Experts: David J. TherouxType: TelevisionIssues: Fiscal Policy/Debt, Land Use
P.J. ORourke On the Wealth of Nations
Recorded: Friday, February 9, 2007
Part 1 |
Part 2
In this hilarious and insightful examination of Adam Smiths work, P.J. shows us why this seminal book on economic liberty is so relevant today and why it has been so revolutionary.
Experts: P. J. ORourke, David J. TherouxType: TelevisionIssues: Economists, History (International)


text:
- 88Promote
Art Print
music unitesby Mauro Mondin
Collect your choice of gallery quality Giclée, or fine art prints custom trimmed by hand in a variety of sizes with a white border for framing.
ANALOG zine vinyl lp record music colors peace puzzle
thanks a lot pixel404 ! :)
Niiiiice! Great colours & style! ......i love it!
thanks a lot Gian Pietro !! :)
love it!
Buena idea!!
So true, Mauro!!! I sleep with a CD curtain in late Marcus cottage! He made as a room divider and the Moon shines through the skylight, they smile in all colors, softly moved via the wind through the open windows! Wonderful creation, Mauro!
thank you very much Wendy, María and the wonderful Christiane ! :D
Oh Yeah! ✯ ✯ ✯ ✯ ✯ 👍
thanks a lot Wayne !! :)
thank you very much JUSTART !! :)
Amazing design!
thanks a lot Alejandra !! =)
cool artwork!
thank you Irina ! :)
Beautiful~ Love the colors here!
Thank you Julia !! :)
Cool graphic!
thank you so much Phil !! :)
so pretty!
thanks again Tangerine !! :)
great colours!
thanks a lot Eva !! :)
Very Cool!
thank you very much Mark !! :)
Always one of my most favorites, Mauro!!!***
thanks a lot Christiane and Kristijan !! :)
Nice work.
thanks a lot YAP9 !! :)
thanks a lot AvHeertum !! :)
See More Comments


text:
Adventure Is Out There Pillow
No longer available
Go searching. Add a fun accent to you bed or sofa with this embroidered pillow. It features a cotton-poly blend shell in a dark blue palette and comes conveniently prefilled.
60% cotton, 40% polyester shell in Nightshade.
Comes prefilled.
Embroidered text.
Made in India.
Online/catalog only.


text:
Fuels made from renewable, natural processes, including Biodiesel such as "FAME" (Fatty Acid Methyl Ester) or "FAEE" (Fatty Acid Ethyl Ester), Biogas, Bioethanol, and Biobutanol.
Biofuels can have different characteristics to conventional refined fuels, depending on the quality of the bio-extender they may potentially polymerize with heat, therefore testing of both bio-extender and finished blends is important. Testing helps to protect engines and fuel pumps from potential damage and deposits caused by poor stability, organic insoluble matter and water; also contamination from metals or bi products from the trans-esterification process.
Biodiesel generally have higher densities than mineral diesel (EN 590 820-845 kg/m3 at 15°C). Density increases with a decrease in chain length and with unsaturation. This can impact on fuel consumption as fuel introduced into the combustion chamber is determined volumetrically.
Viscosities of neat vegetable oils are many times higher which leads to serious problems in unmodified engines. The increase in viscosity results in poor atomization and incomplete combustion which leads to coking of injector tips. This results in engine power loss. Biodiesel still has higher viscosity than mineral diesel (3.50-5.00 mm2/s at 40°C vs 2.00-4.50 mm2/s). Viscosity decreases with unsaturation but increases markedly with contamination by mono, di or tri glycerides.
Pure rapeseed methyl ester has a flash point value of up to 170°C. This method is therefore looking at residual components within the fuel that are combustible, especially methanol which is a particular hazard due to its invisible flame.
Sulphur emissions are harmful to human health and high sulphur fuels cause greater engine wear and in particular shorten the life of the catalyst. Biodiesel derived from pure Rapeseed oil will contain virtually no Sulphur, however FAME derived from animal sources may contain significant quantities.
The Carbon Residue is the material left after evaporation and pyrolysis of a sample fuel. This is a measure of the tendency to of a fuel to produce depositis on injector tips and the combustion chamber. For FAME samples it is an indication of the amount of glycerides, free fatty acids, soaps and catalyst residues remaining within the sample
This serves as a measure of ignition quality. This is the most pronounced change from vegetable oil to the transesterified product. Fuels with low cetane numbers show an increase in emissions due to incomplete combustion. Palm Oil and Tallow derived biodiesels have the best cetane numbers.
Ash describes the amount of inorganic contaminants, such as catalyst residues, remaining within the fuel. Ash is related to engine deposits on combustion.
As FAME is hygroscopic it can pick up water in storage and as such there can be problems meeting the specification. At around 1500 ppm the solubility limit is reached and the water bottoms out. Free water promotes biological growth and the reverse reaction turning biodiesel to free fatty acids.
Total contamination is defined as the insoluble material retained after the filtration of a heated sample over a standardized 0.8m filter. FAME samples with high quantities of insoluble materials tend to cause fuel filter and injector blockages. High concentrations of soap stock are normally associated with high total contamination.
This is defined as the likelihood to cause corrosion to copper, zinc and bronze parts of an engine. A polished metallic strip is heated at 50°C for 3 hours, washed and compared to standards. Corrosion is likely to be caused by free acids or sulfur compounds. However FAME gives consistently good results in this area and is unlikely to fail due to the low sulfur content.
The Oxidative stability specification is defined as a minimum Rancimat induction period of six hours. Essentially a fuel is heated at 110°C in a constant air stream and the formation of volatile organic acids is detected. This property relates to the overall storage stability of the fuel and the higher the degree of unsaturation (double bonds) within the FAME molecules gives a decrease is oxidative stability. This can be improved with the addition of antioxidant additives.
Acid value is a measure of mineral acids and free fatty acids contained in a fuel sample. It is expressed in mg KOH required to neutralize 1g of FAME. High fuel acidity is linked with corrosion and engine deposits.
Iodine number is a measure of total unsaturation (double bonds) within the FAME product. It is expressed as the grams Iodine required to react with 100g of FAME sample. High Iodine value is related to polymerization of fuels, leading to injector fouling. It is also linked to poor storage stability.
This is measured using gas chromatography and is restricted to esters falling within the C14-C24 range. It is ultimately a test for reaction conversion. Linolenic and polyunsaturated esters are controlled as they have been shown to display a disproportionately strong effect on oxidative stability.
Methanol can be removed from FAME by washing or distillation. High methanol contents pose safety risks due to the very low flash point of methanol.
There is a limit on the mono, di, and triglycerides of no more than 0.80%, 0.20% and 0.20% respectively. Total glycerol is the sum of the bound and free glycerol and must not exceed 0.25%/ Failing to meet the spec implies low conversion to ester and deposit formation on injectors and valves.
Sodium and Potassium are limited to a combined 5ppm. These arise from the addition of catalyst, and result in high ash levels in the engine.
Calcium and Magnesium are limited to a combined 5ppm. These may arise from the addition of hard water in the washing process. Calcium and Magnesium soaps have been related to injector pump sticking.
The phosphorous limit is approx 10 ppm and normally arise from phospholipids within the starting material or from addition of phosphoric acid in the production process. High phosphorus fuels are suspected of poisoning catalysts and increasing emissions.
Cold-Filter Plugging Point is considered to be a suitable indicator of low temperature operability. It defines a temperature at which a fuel is no longer filterable within a specified time limit.


text:
The table below looks at the statistics for knowledge and experience of Sakonnet products and/or services in IT contracts advertised for the England region. Included is a guide to the average contractor rates offered in IT contracts that have cited Sakonnet over the 3 months to 1 May 2016 with a comparison to the same period in the previous 2 years.
Note that daily contractor rates and hourly contractor rates are treated separately. When calculating average contractor rates, daily rates are not derived from quoted hourly rates or vice versa.
The figures below represent the IT contractor job market in general and are NOT representative of contractor rates within Sakonnet Technology, LLC.
The following table is for comparison with the above and provides statistics for the entire Vendors category in contract jobs advertised in the England region.
This chart provides a 3-month moving total of IT contractor jobs citing Sakonnet across the England region as a proportion of the total demand within the Vendors category.


text:
Christina Aguilera – 2 Outfits and a Make-up Mess
April 30, 2009 in 1 Girl 2 Outfits, Celebrity Oops, Christina Aguilera by Versus
Oops! Like the initial green eye make-up and red lipstick weren't enough… looks like Christina had a wild rough night that ended with a messy make-up!
Looking good weight-wise, and looking good in jeans, seems like she's settled at this healthy, slim & curvy figure… but honestly, I'm not getting her hairstyles… or make-up style.
Share your thoughts!


text:
Choose the pre-pay option for a $5 discount ($60 fee) and an extra hour (doors will open at 5pm for those that have pre-paid!) More pre-pay information.
Foot Size: 8
Usual Pedicure Type: French, hot pink, deep red
Favorite Shoes:
Do I have to pick?! I adore all kinds of shoes, from wickedly tall platform & fetish heels to designer shoes like Jimmy Choo. I have a huge collection and get a sexy charge when I wear them, and it's even better when there is someone there to genuinely appreciate them like I do!
What's your favorite thing about your own feet?
My toes! I love attention paid to My toes, I usually make My foot worshiper kiss each and every one, and then slide their tongue in between each and every one…
What's your favorite thing about having your feet worshipped?
How relaxing it can be, and how much fun it is to feel My toes wiggling in a happy mouth!
What's your favorite thing about being the Hostess of Footnight New England?
Bringing together men and women who enjoy sexy, safe foot play. It's such a wonderful experience to see people fulfilling their lifelong dreams of kissing and worshipping feet!
Is there anything else you'd like to mention?
Though I don't usually do sessions during Footnight events, occasionally it does happen with those that are patient and respectful. I do book private sessions so if you're interested in having a bit of My un-divided attention, feel free to ask Me about it at Footnight or send an email to email@example.com
Foot Specialties
Super Smelly Feet - I love to leave My socks on for a couple of days until they are wickedly pungent! I've been told the scent is absolutely intoxicating ; )
Trampling – With barefeet, sneakers or high heels, trampling has brought Me lots of joy and giggles whether it's light or hardcore!
Foot Domination – I will instruct you exactly how to worship MY feet to My satisfaction.
Boot Fetish – My huge selection contains boots of all kinds and styles for devoted boot worship.


text:
September 19, 2012
Missouri quarterback Corbin Berkstresser throws during Saturday's game against Arizona State. Berkstresser was hard on himself this week, despite leading his team to victory in his first career start.
Stories this photo appears in:
Missouri's Berkstresser is his own toughest critic
Missouri quarterback Corbin Berkstresser may have no bigger critic than himself. When asked how he would grade his performance Saturday against Arizona State, the redshirt freshman said a five out of 10.
Use the comment form below to begin a discussion about this content.
Please review our Policies and Procedures before registering or commenting


text:
This is a group for all people that love Project Zomboid. (you don't say! :D) Here you can post your adventures, help other people, make friends, etc. Later when the Co-op function multiplayer is introduced we could probably even join arms and DIE together ;)
Here it is guys! This way you can look at some short footage of what is to come next update.
I asked permission three times but never got a single reply so I made it anyway, hope you enjoy it.
This took away 6 hours of my time :) But I'm happily doing it for you!


text:
Category: Gadgets
New in the App Store: Unicorn by Sound Of Stereo (New WebApp)
In celebration of the release of their newest EP, Unicorn, Sound of Stereo has teamed up with Apple to bring you a fun and exciting app to help spice up all your photos. The program, aptly titled "Unicorn by Sound of Stereo", allows users to add a variety of unicorn-inspired themes to pre-existing photos within their personal albums, or you can also snap a fresh new pic and accessorize it with some majestic accoutrements.
Download the app now for FREE from the App Store and be sure to scope out all the tracks on the EP!
There is also a Sound Of Stereo Magical Web App available now as well…
Click here or the below image to test it out.
The #AOKIFY iPhone/iPad App is finally here!!!
Now at the close of the year the rock 'n' roll star of the electronic world, Dim Mak label boss Steve Aoki, is pleased to announce the release of his first official app, #AOKIFY. Released today, October 18th, this free app is available now on iPhone and iPad devices (Android coming soon).
DMX Vs. Computer (Video)
I've watched this video a few times now and I'm certain he (DMX) is very serious about not knowing how to use Google or a laptop for that matter. I'm so glad Power 105.1 captured this moment and wasn't scared to post it on the internet for everyone to see (laugh at). His expressions after typing his name and hitting 'enter' are classic, right up there with his description of waiting for music to load… I think each time I watch this I get another year younger.


text:
Treat yourself to the best in indoor/outdoor So Cal living. Move in Ready. New Paint in and out. Relax and enjoy as if you were on vacation every day. Sweet 3 BR 2 BA updated home with central AC. New stove in the open kitchen with garden window. Gracious, welcoming front yard with brick walkway and plumeria. Enchanting front and back yards with beautiful landscaping including a Meyer Lemon tree, bougainvillea, and beautiful lawns and enchanting ficus covered walls. Automatic sprinkler system for easy care. Two car garage with shelving, work area plus large level driveway for 4 more cars.
# of Bedrooms: 3
# of Full Bathrooms: 2
Single Family Home


text:
SMACSS: Categorizing CSS
ADC Presents
Views: 2,609
Share this Episode
Adjust your embed size below, then copy and paste the embed code above.
442 x 256
515 x 296
640 x 367
Custom Size
Width: px Height: px
Community Translation
Your transcript request has been submitted.
Adobe TV does its best to accommodate transcript requests. It can take a few weeks for the transcript to become available in the Community Translation Project, so keep checking back.
About This Episode
Jonathan Snook discusses why you should categorize the various functions of the CSS code within your project (base, layout, module, state, and theme) as well as how each element works within the design.
Runtime : 00:03:17 Added : 09/05/2012
About this show
ADC Presents
The Adobe Developer Connection (ADC) is your source for technical articles and how-to videos that cover Adobe developer products and technologies.
Older Episodes
Next episode in this show
Other Suggested Episodes
Related Shows


text:
This user is currently not following anyone.
No one is currently following this user.
Sorry, there are no photos available.
to the Campbell family. I have cried with your family for the loss of both your son. May your family come together and grieve together...
I would be doing time. Rich or poor makes no difference to me. You touch one of my kids like this and there would be no trial, but my...
Back in 1996 I worked at T-N-T next door to Slims. SM3 would send the boys over to the store all the time to buy things with Hundred...
Skip to News
« back
next »
Amarillo Globe-News ©2016. All Rights Reserved.


text:
Real Housewives of Atlanta
Wendy Williams Calls Porsha Stewart Dumb — Right to Her Face!
Wow, you guys, this is pretty messed up. Porsha Stewart recently appeared on The Wendy Williams Show only to have the host call her stupid right to her face! OK, maybe Wendy didn't use that actual word, but she straight up told Porsha that she's "less than smart," not to mention "spoiled."
Within minutes of taking the stage, The Real Housewives of Atlanta newbie admitted that she's currently living with her mama and she also made the mistake of mentioning how much her mother totally spoils her, to which Wendy replied, "Well, that's part of your problem."
She then went on to tell Porsha, "Your behavior is less than smart."
But, Wendy insisted that it takes guts to be honest when you're sitting on her purple couch and that her insult comes from concern over Porsha's future.
"You are a gorgeous woman, who has the world at your feet," she assured Porsha, adding, "I think that you should live on your own. It seems like you've been coddled and spoiled by your mother and by Kordell, and that never helps us as women when we get out in the world."
"That's true," Porsha admitted, before pointing out that right now she needs her mother's support and strength before she can face the world again.
When Wendy reiterated that she'd like to see Porsha snag a one-bedroom apartment of her own, Porsha teased, "You might…keep watching, Wendy!"
Do you agree with Wendy that Porsha needs to stop letting others take care of her and move out on her own? Share your thoughts in the comments section below!


text:
Apply For A Loan
To apply for a personal or business loan, select the type of loan below and provide the initial information! The forms are in Adobe Acrobat Reader (*.PDF) format and you can download the software free at adobe.com. Mail your application to: TransCapital Bank Attn: Loan Officer - 8850 W. Oakland Park Boulevard - Sunrise, FL 33351 or fax it to (954) 452-3523. With questions call (954) 452-3513 or toll free (877) 339-BANK.
FOR A PERSONAL LOAN: Fully complete the application below and (a) if employed by others, provide a copy of your most recent pay stub, or (b) if self-employed, provide the last 3 years personal and business (if not sole proprietorship) tax returns. If applying for an unsecured loan, also fully complete the Personal Financial Statement.
Personal Loan Application in *.PDF format Personal Financial Statement form in *.PDF format.


text: 500 pts Policital Trivia <KSFA VIP What country is currently in upheaval? Click here to see the answer. Sign in to Participate Category: Trivia Ends: Monday September 16 at 10:59PM CDT Visit our sponsor: Click here to see the answer. Share on Facebook Share on Twitter More Send to a friend! Print this page Pin it! Reddit This! Share on Tumblr! More Ways To Get and Use Points Indoor/Outdoor Movie Screen + ProjectorWin a $300 Amazon Gift CardWin a Breville Juice Fountain Multi-Speed 900-Watt JuicerDEWALT Single-Bevel Compound Miter SawWin $10,000 Cash!Win a GoPro HERO4 SILVER Starter Bundle


text:
Sunday, March 21, 2010
Spring Training Notes
Game IP H ER BB SO HR GO FO
one 2 7 6 0 2 2 2 1
two 3 4 0 1 0 0 5 3
thr. 4 2 0 0 3 0 4 3
for. 2 1 1 1 2 1 2 2
After the HR in the 2nd (when Silva was apparently injured), he also walked and then struck out the following two batters.
It appears the bullpen is cementing up, as Justin Berg has officially made the team, according to Lou. This leaves pretty much one spot for -- hopefully -- Mike Parisi. Berselius examines this at length at Another Cubs Blog.
Also, we discovered last week that Mike Fontenot, in addition to winning the starting second base position, will be the Ryan Theriot's backup SS. This leads me to ask: Why aren't we platooning the second base position?! I'm perfectly happy with young star, Starlin Castro, cast as a full time player in AAA, but I don't see any harm in platooning the second base position, given Fontenot's and Jeff Baker's (relatively small) history of dramatic splits.
2 comments:
Brad - has it been decided that Fontenot is the backup SS yet? Theriot is a guy who plays every day anyway, and if he's injured for a nontrivial amount of time they'll just call up Barney or Castro.ReplyDelete
Just because Lou has said Fontenot is the starter doesn't mean he'll be facing LH starters. Fukudome is the starter in RF but it's clear that Nady was picked up to be his platoon partner
Great points, B.ReplyDelete
Yeah, I didn't really get into the Fonte-backup situation because I also do think it's Castro's job if there's any serious injury. Also, I agree on the Fontenot-Baker platoon thing: they might be platooning, but just calling Fonty the starter because he'll get more time (b/c they will face more RHPs). However, I've just not gotten that indication or impression.
Who knows? Maybe they will platoon -- or maybe Hendrey & Co. have seen something in Fonty's ability to hit lefties, something that his smallish sample size doesn't show? (IIRC, he hasn't had enough PAs vs. lefties to qualify as definitively bad against LHP, per The Book's requirements.)


text:
Carnifex Drummer Shawn Cameron on His Favorite Slipknot Song
Brandon Geist | Sep 28, 2011 | Comments 1 | Tags: Carnifex, Slipknot
With the release of our new Slipknot special collector's issue, we're celebrating Slipknot month on RevolverMag.com, unleashing new interviews, photos, favorite Slipknot song picks from a host of celeb columnists, and much more. So check back right here often. Below, Carnifex drummer Shawn Cameron talks about his favorite Slipknot song:
"My favorite Slipknot song would have to be '(sic).' The song is so aggressive and intense. At the time, it was so different from anything I'd ever heard. It made me try and headbang my face off! It's the first song on the self-titled album of theirs I ever listened to back in the spring of 2000. I jammed with this guy once. After jamming, he gave me that CD to listen to, so I took it home and it changed my life! I couldn't stop listening to it. I went out and bought the Disasterpieces DVD and studied Joey's every move. Slipknot's music has heavily influenced the way I play and the way I write. Raw, heavy, and pissed off."
Photo by David Biskupski
Alert to All Users of the Disqus commenting system: Because of a recent global security issue, the Disqus website recommends that all users change their Disqus passwords. Here�s a URL about the issue: http://engineering.disqus.com/2014/04/10/heartbleed.html
Get our Free Newsletter Here!


text:
Why does my baby choke when he drinks from a bottle?
My 2 month old is mainly breastfed but I am going back to work in a couple days and every time I try to give him a bottle he chokes like it's coming out too fast. I've tried 3 different types of slow flow nipples/bottles but nothing works. He does the same thing when he nurses if I'm engorged at all. I need help and I need it fast! Not sure what we will do if he can't drink from a bottle all day???
Posted: 07/31/2013 by angelacharvat1
Mom Answers
Sort by: best answers | most recent answers
1 - 3 of 3 answers
I was going to say try a slow-flow nipple. Just keep trying to find one that works. But you also might try feeding him sitting up and the bottle horizontal so that it doesn't just pour into his mouth.posted 07/31/2013 by a BabyCenter Member
Sounds like 2 things: when you are engorged, you may have overactive letdown. Try stimulating letdown, catching the initial spray in a towel and then going back to feeding. As far as the bottle, this is a great resource: http://amywest.co/2013/07/23/on-bottle-feeding/ Basically, babies can't control the flow from a bottle the way they can from a breast and so it can overwhelm them and cause choking (and overeating)posted 08/02/2013 by Lulu_28
have you tried a preemie nipple?posted 07/31/2013 by a BabyCenter Member
Answer this question


text:
May 2, 2016
A business in Duplin County went up in flames Saturday night and was completely destroyed. According to officials two firefighters were injured while fighting the blaze.
The business, Beulaville Liquidators, is located at 3525 E NC 24 Hwy.
According to officials the flames began around 6:15 p.m. and it took 8 different fire departments and 75 fire officials to fight the fire.
The business was a 7900 square foot building and the estimated damage is worth around 1 million dollars.
According to officials the roof collapsed while firefighters were inside and two firefighters were hurt. One needed medical attention.
The employee who was there got out just in time.
Investigators are on the scene Sunday afternoon now trying to figure out what started the blaze.
Click Here to access the online Public Inspection File
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.


text:
RSV1000R Mille / Factory
RSV1000R Mille / Factory
Techmount 12mm - 14mm Accessory Stem Mount (expansion nut with spacer), black or silverStem mounted accessory holder for attaching AMPS/RAM-B-238-compatible devices and cradles. Stem mount held in place with a rubber expansion nut to fit stem hole sizes from 12mm to 14mm. Learn More$74.95
Techmount GEN 4 Top of 53mm Fork Tube Euro Mount for Select Aprilia, Ducati & Moto Guzzi in Black or SilverEuro Mount to clamp to top of 53mm fork tube for Techmount GEN 4 Mounting systems. Learn More$74.95


text:
May 4, 2016
With so many birth control options available today, how do women know which method is the best choice for them? Obstetrician and Gynecologist, Dr. Kinion Whittington joins us today to discuss one of the more popular options right now, the estrogen –free IUD.
Click Here to access the online Public Inspection File
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or firstname.lastname@example.com.


text:
Limbo Headed to Playstation 3 and PC
I've been living with both a PS3 and Xbox 360 — and I've been gaming on the PC since I was a wee lad — for so long that I sometimes forget that there are people out there who only have one major home gaming platform. This is one of the moments that reminds me that that is the case.
Limbo, the so-far Xbox Live-exclusive platformer from PlayDead is heading the Playstation 3 and Steam in July. That word comes from a tweet by studio founder Dino Patti.
This is good news, of course. The more people that are able to experience a game — especially one we loves as much as we do Limbo– the better. As they say in Sandford, Gloucestershire: "The greater good."


text:
It was a banner year for Hockey Brandon's female teams this season, and one the organization hopes to build on.
Three squads took home provincial titles this season — the Atom Yellow Jackets and the Peewee Wheat Kings won their respective A/B championships, while the Midget Wheat Kings won the C/D title — as well as a bronze medal in the Bantam A/B division.
Please subscribe to view full article.
Already subscribed? Login to view full article.
Not yet a subscriber? Click here to sign up


text:
Follow The Republic on social media:
Willard Wischmeier, 81, of Seymour, died at 2:30 a.m. Wednesday, Oct. 30, 2013, at his residence.
He was former owner of Wischmeier Grave Services and was a retired farmer. A lifelong member of St. John's Lutheran Church at Sauers, he was a member of Sauers Men's Club and Sauers C Dartball Team and had been an active member of Indiana Farm Bureau since 1952. He loved being with his family, attending his grandchildren's sporting events, fishing, traveling and riding his golf cart. He took great pride in maintaining the cemeteries he was involved with.
Funeral will be conducted at 10 a.m. Saturday at St. John's Lutheran Church, Sauers, with Pastor Craig Muhlbach officiating. Calling will be from noon to 9 p.m. Friday at Spurgeon Funeral Home in Brownstown, and from 9 a.m. until service time Saturday at the church. Burial will be at the church cemetery.
Memorial contributions may be made to St. John's Lutheran Church, Sauers, or St. John's Lutheran School, Sauers.
Born in Seymour Feb. 22, 1932, Mr. Wischmeier was the son of Martin and Lena Surenkamp Wischmeier. He married Marcella Hackman Feb. 4, 1951, at St. Paul's Lutheran Church, Wegan.
Survivors include his wife; a son, Dwight (Robin) Wischmeier of Seymour; daughters, DeAnn (Doug) Maxie and Danielle (Charlie) Murphy, both of Seymour; a daughter-in-law, Linda (David) Isom of Seymour; a brother, Melvin (Emy Lou) Wischmeier of Seymour; grandchildren, Shawn (Kelly) Wischmeier, Randi Wischmeier, Heather (Tony) Henson, Adam Wischmeier, Amber Wischmeier, Alex Wischmeier (Megan Hall), Jennifer Speck, Michael Maxie (Mahala Wheeler), Mitchell Maxie, Melissa Maxie, Mark Maxie (Alison Carpenter), Telissa Murphy, Erin Murphy and Andrew Murphy; and great-grandchildren, Sydnee, Tristan, Whitley, Chaz, Nichole, David, Steven, Carter, Ethan, Austin, Jordyn, Carter and Dylan.
He was preceded in death by his parents; a son, David Wischmeier; a grandson, Nicholas D. Wischmeier; a brother, Erwin Wischmeier; and two sisters, Wilma Stuckwisch and Ella Benter.
All content copyright ©2016 The Republic, a publication of AIM Media Indiana unless otherwise noted.
All rights reserved. Privacy policy.


text:
Kat Dennings, star of the hit comedy series "Two Broke Girls," recently brought the va-va-voom to the red carpet. The actress was glowing in a deep blue gown with a plunging neckline while attending the 2012 TCA Summer Tour for CBS, Showtime and the CW.
Dennings paired her show-stopping gown with equally as sassy makeup. She started by accentuating her full pout with muted red lipstick. Dennings then applied pink blush on the apples of her cheeks and added major drama on her eyes. The starlet began the look with jet black eyeliner on her top and bottom lids, she then applied tons of silver eyeshadow on top up to her brow bones. The actress completed the style with volumizing mascara.
Although Dennings' makeup was good, her dress definitely garnered all the attention from fans and critics alike. The blue dress had off-the-shoulder sleeves and tons of ruching down the body of the design. The form-fitting frock showed off her womanly curves, while a slight slit up one leg accentuated her toned gams. Dennings paired the dress with black platform pumps and her hair down in big curls.


text:
Product review by Carrie Wilbur, The Old Schoolhouse Magazine, LLC, August 2007
Another review:
Rosetta Stone Latin Level 1 (Homeschool Edition) is a foreign
language program for the computer. Included in the box is the software,
an audio companion, a cd with supplemental materials, a parent's guide,
a user's guide, and a headset with microphone.
Rosetta Stone Latin is an immersion foreign language program.
Level 1 covers "basic conversational skills, including greetings and
introductions, simple questions and answers, shopping, and much more." There
are three units in Level 1, and each unit is broken down into four
lessons. Unit 1 covers "Language Basics," Unit 2 covers "Greetings
and Introductions," and Unit 3 covers "Work and School." The Homeschool
Edition allows for multiple users and allows the parent to track each
student's progress through what is called the "Homeschool Dashboard." From
there, the parent is able to assign or edit the curriculum for each
student and look at, save, or print individual progress reports.
The Homeschool Edition of Rosetta Stone Latin includes various lesson
plans to choose from, or you can create your own based on your objectives. It
is easy to navigate the software and choose from a full-year program (which is
the most extensive path), a standard program (which streamlines the program and
is recommended for students who learn languages quickly), a reading and writing
focus, or a speaking and listening focus. You can customize a program for each
child using the software, and from the "Homeschool Dashboard" you can go in and
edit each child's course at any time. Depending on which program you choose,
the various activities include listening, reading, speaking, pronunciation, writing,
grammar, and vocabulary. Rosetta Stone Latin also includes a speech
recognition component. The student speaks words into the included microphone,
and the software analyzes the student's pronunciation.
In addition to the software, an "Audio Companion" is also included. This is a
set of three CDs (one for each unit), and they are broken down by lesson. Each
lesson is further broken down into pronunciation, vocabulary, phrases, speaking,
and conversation, except for the first two lessons. (Lesson One doesn't include
speaking and conversation, and Lesson Two doesn't include conversation.) The
literature says a native speaker is used, but since Latin isn't a spoken language
this isn't possible. The speaker on the CDs trills the letter "r" and speaks
with what sounds like a Spanish accent.
The "Supplemental Education Materials" CD includes the course contents, which
is a script for each lesson, along with an index to all the words in the program.
However, this is all in Latin, and there is no English translation.
This is a very user-friendly program. The software is designed very well and
is very intuitive. I was able to easily install the program, assign a course
to my 9-year-old son, and step away while he worked through the lessons. He really
enjoyed Latin using Rosetta Stone, except for trying to speak it with the Spanish-type
accent. However, because Latin is a dead language, I think the student misses
out on a lot using Rosetta Stone. Conversing fluently isn't the typical goal
when one decides to teach or learn Latin. It's often the logic behind the language
or learning Latin vocabulary that drives one to study Latin. Because this program
focuses on teaching the student to be a fluent speaker of Latin, I don't feel
it adequately explains or teaches the logic behind Latin, therefore leaving out
one of the huge benefits of studying Latin to begin with.
I think the Rosetta Stone software is fabulous, and I would not hesitate to use
it for a living language. However, I would not recommend it for a stand-alone
Latin program. And with a price tag of $229, it's quite expensive to suggest
as a supplement.


text:
Ritholtz's 10 Monday Reads: Market Insanity and the 'Next Silicon Valley'
Barry Ritholtz is a Bloomberg View columnist writing about finance, the economy and the business world. He started the Big Picture blog in 2003 and is the founder of Ritholtz Wealth Management, an asset management and financial planning firm.
Read More.
Read More.
We're back to the grind. Ease the transition with these reads:
- Notes from the DoubleLine Lunch with Jeffrey Gundlach, Spring 2014 (Reformed Broker)
- Dealing With Market Insanity (Trader Feed) see also Some Quick Thoughts Regarding the Tape . . . (Phil Pearlman)
- Five Burning Questions Investors Have About Markets Right Now (Financial Post)
- Rotate, Reflate, Reflect, Placate (FT Alphaville)
- The Problem With Profitless Start-ups (NY Mag)
- Clements: Dividend funds to retire on: An allocation can help preserve capital (WSJ)
- The Dark Side of Investment Stories (ThinkAdvisor)
- Why Won't Washington Take on Wall Street's Biggest Crimes? (The Atlantic)
- Why the 'Next Silicon Valley' Is Always Silicon Valley (The Atlantic)
- The 13 Gods of the Internet Pantheon (College Humor)
What are you reading?
Stock-Market Jitters Put Investors at Ease
This column does not necessarily reflect the opinion of Bloomberg View's editorial board or Bloomberg LP, its owners and investors.
(Barry Ritholtz writes about finance, the economy and the business world for Bloomberg View. Follow him on Twitter @Ritholtz.)
To contact the author on this story:
Barry L Ritholtz at firstname.lastname@example.com


text:
I love Superbowl parties. I mean, what other time is it okay to sit around the tv, holler and drink and eat junk food with your friends for hours? I know, it's not the healthiest of activities, but it's the Superbowl, people!!! Even if your team didn't make it to the championship (our sad, pathetic Chargers didn't), doesn't mean you can't have a little fun? But seriously, let's live it up, every now and then, and not count calories for ONE DAY. We have all week before and after the game to burn off the calories we gorged on during this event!
I heard on the radio that the number one food consumed during the big game is chicken wings. If prepared in the broiler or grilled, it's actually a healthy, protein rich treat.
The next two, not so healthy. Pizza comes in second, and my favorite, chips & dip, come in third.
Which brings me to one of favorite dips, Easy White Queso.
My friends and I love to meet up at this fabulous neighborhood Mexican restaurant, Miguel's Cocina. They bring you chips & salsa, of course, but they also bring you a little bowl of white queso. Seriously, it's just not enough for us to share, and we always request more!
Everyone wanted me to come up with a recipe for this queso, and this is my version.
And it's super easy, too. Just two ingredients, because I'm a simple girl: pepper jack cheese & heavy cream.
This dip stays creamy and smooth even after it cools down, which is key. Like the little black dress, you can dress this dip up or keep it low key. Feel free to add more chiles, chorizo or even salsa to the mix.
Just pass the tortilla chips and a cold margarita, and give me the bowl please.


text:
Sudden storm drenches area
Tuesday, March 8, 2011
A sudden storm hit Friday afternoon, March 4, drenching the area with heavy rain, accompanied by small hail and heavy wind. Most of the 1.05 inches of precipitation reported fell within a few minutes, quickly flooding several areas of Business 50 in California and overwhelming the drainage systems in the city.
For more of this story check out the March 9 issue of the California Democrat.
Use the comment form below to begin a discussion about this content.
Please review our Policies and Procedures before registering or commenting


text:
Hallmark Channel have announced plans to produce their first ever 'Kitten Bowl' to air opposite the Superbowl next Superbowl Sunday. Naturally, a bowl full of kittens (as pictured above) is a little more literal than what Hallmark is planning, but I doubt any readers will complain about my selected image.
The 'Kitten Bowl' has never before been produced by Hallmark Channel nor anywhere else, yet it may seem familiar--that is because for years Animal Planet has been producing the 'Puppy Bowl' on Superbowl Sunday, featuring their ever-popular kitten halftime show. Hallmark's 'Kitten Bowl' will be airing in direct competition with the 'Puppy Bowl,' reawakening the age-old struggle between dog-people and cat-people.
Hallmark Channel promises that 'Kitten Bowl' will be "the greatest feline showdown in cable television history." They had to specify cable and not network, presumably due to previous antics of famed cats Sylvester from 'Looney Tunes' or Tom from 'Tom & Jerry.' Kittens, taken from animal shelters (and will be available for adoption) will compete in a obstacle course that boasts "hurdles of varying heights, A-frame Alpine Scratchers, tunnels, hoop jumps, and weave poles. Lures, like laser pointers, and toys on a string will be used to get the kittens through the course, but food will not [be] allowed." Hallmark also ensures that cuteness of the felines will be "key to the game" in some yet-to-be-explained capacity.
Hallmark Channel plans to air 'Kitten Bowl' on Superbowl Sunday at 12:00pm, then again at 3:00pm, then again at 6:00pm. Animal Planet's popular 'Puppy Bowl' airs at 3:00pm and then repeats until 3:00am--that's right, twelve hours of total nonstop puppy action. Upon learning of Hallmark's 'Kitten Bowl' plans, Animal Planet released the following response:
"You've GOT to be kitten me! With the record-breaking success of Animal Planet's 'Puppy Bowl,' our famous Kitty Half-Time Show and the huge viewership for our new live Kitten Cam, we're not surprised by a 'copy cat.' After all, imitation is the sincerest form of flattery. We're just happy that pet adoption is being promoted and more animals are finding their fur-ever homes."
Animal Planet seems rather confident that their Superbowl Sunday tradition shall fare well against this new furry competitor. Where will your heart lie come Superbowl season? The 'Kitten Bowl,' the 'Puppy Bowl,' or with the usual victor of the day, Superbowl commercials?


text:
View: In a Room |
closeLarger Image
John H. Johnson - 1961
Photographic Print
Item #: 15319245164A
Size and print type
Ships in 1-2 days
Photo licensed from Johnson Publishing Company, publisher of EBONY and JET magazines.
Former Attorney General Robert F. Kennedy, Johnson Publishing Company founder John H. Johnson, U.S. Ambassador to Ivory Coast R. Borden Reams and former Assistant Secretary of State G. Mennen Williams are photographed attending an event.
This photographic print is digitally printed on archival quality paper with vivid color and exceptional detail, suitable for museum or gallery display.
Other ways to order:
Call Us: 1-800-952-5592div_lc_sb_pp_01||http://chat.art.com/WebChat/Main.aspx?QueueName=WWW.ART.COM&langiso=en&countryiso=US|ProductPage|Available Chat Link Clicked|Bottom||img_lc_sb_pp_01|floatLeft global-image-sprite|800-952-5592
If for any reason you are not completely
satisfied with your purchase, you can
receive a replacement or refund within
30 days Learn More
Ship time indicates the typical time it takes for your item(s) to leave our facilities. This includes any framing or customizing services ordered as well as careful packaging to prevent damage in transit.
Items that ship same day normally leave our facilities on the same business day if your order is placed before 5:00pm EST.
Orders that contain multiple items with different ship times will be shipped out based on the item with the longest ship time.
Shipping FAQ
Shipping Rates
Photos To ART
Decorate with photos you love. With Photos to Art, you can transform your favorite snapshots into one-of-a-kind works of art that you'll be proud to hang on your wall. Choose from artistic canvas, custom framing, wood mounting and more to update your décor with art that is totally you.
Custom Framing
Each piece of custom framed art is handcrafted and hand-signed by a professional artisan. Our assortment of high quality frames includes classic styles and the latest design trends, allowing you to fully personalize your art. Choosing a frame is fun, easy and affordable, and your satisfaction is 100% guaranteed.
Recommended For You
- You'll Like
- retailerId
- 3b3227d2
- view
- productId
- 9210036


text:
Damon Farmer, sand sculptor
Damon Farmer, an accomplished artist in everything from oil and canvas to computer graphic animation, does much of that work on his Woodford County farm. But the medium for which he's best known requires travel: He roams all over the world creating fantastic sculptures in sand.
His talents in this distinctive and transitory medium have earned him top accolades in cities close to home, like Louisville and Owensboro, and as far away as Italy and China. Some recent projects have included the Presepe di Sabbia (Nativity of Sand) in Jesolo, Italy, which he worked on for the third year in a row in 2004, and a "Sultans of Sand" exhibit in that same city in spring 2004. The ancient Egypt-themed display drew almost 100,000 visitors during its 30-day existence.
In September 2004, Damon won the Sculptor's Choice award and the third-place medal at the North American Solo Sandsculpting Championship in Virginia Beach. He has also created pieces for Kentucky public art projects like Dynamic Doors, Show of Hands, and Horsemania.
| Mixed Media Home | Guests | Online Video | Events Calendar | Arts Links | Host | About the Show |
| KET Arts Home |


text:
Hi, everyone in Tech-Land. Nik here with yet another question to ask.
When I was in Air Cadets, I was taken up numerous times in a Cessna 172, and even on one occasion flew on a Beech B58 Baron as part of my aviation training through the RCAC (Royal Canadian Air Cadets).
This question has been bugging me for four years, and I haven't found any answers yet, but how do the fuel mixture controls on a propeller-driven airplane work, exactly? I understand lean and rich, but everything else is Greek to me.
To refine the question: when we were up at high altitude (9,000 to 11,000 feet), the Pilot-in-Command pulled the mixture lever(s) back about halfway between 1/4 and 1/2 between lean and rich settings. Why do propeller pilots do this? Does it have something to do with engine control? Fuel mixture in the cylinders? Fuel economy? An explanation would be greatly appreciated.
Thank you,
Please check your spelling (press "Check Spelling" above)
©Copyright 2016 Demand Media, Inc. All Rights Reserved


text:
Whether you want to provide an annually given or endowed scholarship/grant, your investment in Ozark students will make a huge difference in their preparation for Christian leadership.
There are several ways you can provide scholarships that will be awarded to worthy students in need of financial assistance. All recipients must meet minimum guidelines established by the college administration and, when appropriate, you may also set specific recipient guidelines.
Named and/or endowed scholarships are welcomed. These scholarships are often named in memory or honor of an individual or a family. Named or endowed scholarships require financial minimums for both investment and distribution.
For more information regarding how your gift may be used for student scholarships, please contact the Development Department today.
Complete an online Scholarship Exploration Form >>
Download a Scholarship Exploration Form >>
Your financial and material gifts can help train men and women for Christian service!
Get the latest Ozark news!
You can help Ozark Christian College reach the world for Christ, one leader at a time!
OCC is involved with several social networks. Connect with OCC and our network of alumni, friends, employees and students.
Changing the world.One leader at a time.


text:
Pacific Palisades News
PACIFIC PALISADES—The next phase to construct a storm water diversion structure on Temescal Canyon Road is scheduled to begin later this month and continue through October. This construction phase is part of a two-year $8 million project to help the City of Los Angeles remove bacteria and other pollutants from urban runoff from reaching Will Rogers State Beach and other adjacent coastal waters.
Excavation and installation of shoring for the detention tank will take place with operating hours of Monday to Friday from 7am to 5pm and some weekend work possible, according to the project's official website, http://www.temescalcanyonstormwaterproject.org. The park's play area and restrooms have been closed as part of the project and will be replaced.
Potential traffic impacts have been detailed on the project's website which is urging motorists to plan accordingly while traveling on Temescal Canyon Road. Going uphill, two traffic lanes will remain open at all times. Meanwhile, approximately 1100 feet of street parking will be removed to make room for traffic lanes and a bicycle lane. Approximately 850 feet of the dedicated bicycle lane will be removed. Therefore, cyclists may share the traffic lane with vehicles or use the sidewalk.
As for travel downhill, two traffic lanes will remain open at all times. However, 1400 feet of street parking will be removed to make way for traffic lanes and a bicycle lane. A continuous, dedicated bicycle lane will be available at all times during the construction period.
The project is one of more than 30 projects funded by theProposition O Clean Water Bond approved by voters in 2004. The measure funds storm water infrastructure developments and enhancements that will help the City of L.A. comply with mandates from the water quality agencies like the California Coastal Commission and U.S. Environmental Protection Agency. The project is being implemented by the City of L.A. Department of Public Works Bureau of Engineering in collaboration with the Bureau of Sanitation. Construction is expected to be completed by Fall 2013.
© Copyright 2007 by canyon-news.com